Clinical Trials Logo

Metastatic Leiomyosarcoma clinical trials

View clinical trials related to Metastatic Leiomyosarcoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05174455 Withdrawn - Clinical trials for Metastatic Leiomyosarcoma

Niraparib for the Treatment of Leiomyosarcoma

Start date: December 1, 2023
Phase: Phase 2
Study type: Interventional

This phase II trial tests whether niraparib works to shrink tumor in patients with leiomyosarcoma. Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.